Peritoneal carcinomatosis of colorectal origin: Standard of care [5]

Annals of Surgery

Volumn 244, Issue 4, 2006, Pages 632-633

  Yan, Tristan D ^a,b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

AUSTRALIA; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FRANCE; GERMANY; HUMAN; HYPERTHERMIC THERAPY; ITALY; LETTER; MULTICENTER STUDY; NETHERLANDS; NORTH AMERICA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPAIN; SYSTEMIC DISEASE;

CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PERITONEAL NEOPLASMS;

EID: 33748921262     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000239629.96036.cd     Document Type: Letter

References (17)

1. Koppe MJ, Boerman OC, Oyen WJG, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212-222.
2. Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:747-754.
3. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292.
4. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518-521.
5. Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65-71.
6. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178-186.
7. Schneebaum S, Arnold MW, Staubus A, et al. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol. 1996;3:44-50.
8. Pilati P, Mocellin S, Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol. 2003;10:508-513.
9. Kecmanovic DM, Pavlov MJ, Ceranic MS, et al. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:147-152.
10. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2003;21:3737-3743.
11. Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403-407.
12. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364-367.
13. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
14. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:58-63.
15. Bloemendaal ALA, Verwaal VJ, va Ruth S, et al. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol. 2005;31:1145-1151.
16. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:77-79.
17. Sugarbaker PH. Decreased the risk of a treatment expands its indications. Ann Surg Oncol. 2005;12:868-870.